Cours d'initiation aux circuits à transistors

por Lacour, J
Publicado 1961

Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis...

por Queille‐Roussel, C., Bang, B., Clonier, F., Lacour, J.‐P.
Publicado 2016

Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases

por Montaudié, H., Chiaverini, C., Sbidian, E., Charlesworth, A., Lacour, J-P.
Publicado 2016

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances

por Ständer, S., Yosipovitch, G., Lacour, J.‐P., Legat, F.J., Paul, C., Reich, A., Chaouche, K., Ahmad, F., Piketty, C.
Publicado 2022

Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III r...

por Gottlieb, A.B., Lacour, J.‐P., Korman, N., Wilhelm, S., Dutronc, Y., Schacht, A., Erickson, J., Zhang, L., Mallbris, L., Gerdes, S.
Publicado 2016

In-situ characterization of nanoparticle beams focused with an aerodynamic lens by Laser-Induced Breakdown Detection

por Barreda, F.-A., Nicolas, C., Sirven, J.-B., Ouf, F.-X., Lacour, J.-L., Robert, E., Benkoula, S., Yon, J., Miron, C., Sublemontier, O.
Publicado 2015

Impact de la pandémie COVID-19 sur la prise en charge des patients adultes atteints de dermatite atopique modérée à sévère : analyse complémentaire de l’étude MOVE

por Lacour, J.P., Fougerousse, A.C., Becherel, P.A., Droitcourt, C., Dupuy, A., Falissard, B., Gackiere-Katsogiannou, M., Aubert, N., Thenie, C., Helman, N.
Publicado 2022

Functionalized cationic [4]helicenes with unique tuning of absorption, fluorescence and chiroptical properties up to the far-red range

por Delgado, I. Hernández, Pascal, S., Wallabregue, A., Duwald, R., Besnard, C., Guénée, L., Nançoz, C., Vauthey, E., Tovar, R. C., Lunkley, J. L., Muller, G., Lacour, J.
Publicado 2016

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world se...

por Seneschal, J., Lacour, J.‐P., Bewley, A., Faurby, M., Paul, C., Pellacani, G., De Simone, C., Horne, L., Sohrt, A., Augustin, M., Hammond, E., Reich, K.
Publicado 2020

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate‐to‐severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI‐PSO s...

por Richard, M.‐A., Lacour, J.‐P., Konstantinou, M.‐P., Ruer‐Mulard, M., Joly, P., Aractingi, S., Auquier, P., Pelvet, B., Augustin, M.L., Mahé, E., Chalmers, R.J.G.
Publicado 2020

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

por Fernandez, A.P., Dauden, E., Gerdes, S., Lebwohl, M.G., Menter, M.A., Leonardi, C.L., Gooderham, M., Gebauer, K., Tada, Y., Lacour, J.P., Bianchi, L., Egeberg, A., Pau‐Charles, I., Mendelsohn, A.M., Rozzo, S.J., Mehta, N.N.
Publicado 2022

The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from ASSURE‐CSU

por Maurer, M., Abuzakouk, M., Bérard, F., Canonica, W., Oude Elberink, H., Giménez‐Arnau, A., Grattan, C., Hollis, K., Knulst, A., Lacour, J.‐P., Lynde, C., Marsland, A., McBride, D., Nakonechna, A., Ortiz de Frutos, J., Proctor, C., Sussman, G., Sweeney, C., Tian, H., Weller, K., Wolin, D., Balp, M.‐M.
Publicado 2017

Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE‐CSU

por Sussman, G., Abuzakouk, M., Bérard, F., Canonica, W., Oude Elberink, H., Giménez‐Arnau, A., Grattan, C., Hollis, K., Hunter, S., Knulst, A., Lacour, J.‐P., Lynde, C., Marsland, A., McBride, D., Maurer, M., Nakonechna, A., Ortiz de Frutos, J., Reynolds, M., Sweeney, C., Tian, H., Weller, K., Wolin, D., Balp, M.‐M.
Publicado 2018

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)...

por Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J.‐P., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., Lesiak, A., Kircik, L., Cho, S.H., Herranz, P., Cork, M.J., Peris, K., Steffensen, L.A., Bang, B., Kuznetsova, A., Jensen, T.N., Østerdal, M.L., Simpson, E.L.
Publicado 2020